Mineralocorticoid receptor antagonist in heart failure: Past, present and future perspectives (2024)

2.1. Spironolactone

Spironolactone is a widely used, non-selective aldosterone receptor antagonist marketed since the early 60s that is metabolized extensively in the liver to its active metabolites. Its plasma half-life is 1.4 h, although in CHF patients with hepatic congestion, this duration may increase 5-fold. A maximal drug response is seen 48 h after the first dose. Spironolactone is structurally similar to progesterone, thereby allowing sex-steroid receptor cross-reactivity. This phenomenon accounts for the anti-progesterone and anti-androgen effects observed in some patients treated with spironolactone. Gynecomastia or breast pain is the most frequent side-effect of spironolactone, occurring in about 10% of patients in chronic treatment [19].

2.2. Canrenone

Canrenone is the principal active metabolite of spironolactone, devoid of first-pass effect, and has a long half-life (of 16.5 h). As spironolactone, canrenone is a non-selective MRA, but a lower incidence of anti-androgen side effects has been reported [20]. It is frequently used as an alternative to spironolactone mainly in European countries. Canrenone is also derived from the rapid conversion in vivo of the salt potassium canrenoate, which has shown important anti-remodeling effects in post-infarction LV remodeling [21].

2.3. Eplerenone

Eplerenone is a selective aldosterone receptor antagonist derived from spironolactone but with lower affinity for the progesterone and androgen receptors so it lacks sex-related adverse side effects. Eplerenone is metabolized in the liver by cytochrome P450 (isoenzyme CYP3A4); plasma levels of eplerenone are influenced by concomitant use of inhibitors of CYP3A4, including ketoconazole, itraconazole, ribonavir, and clarithromycin, that are associated with significant increases in its peak levels, whereas inducers of CYP3A4 such as phenobarbital decrease it. Eplerenone has a plasma half-life of 4 to 6 h, and steady-state drug levels are usually achieved 48 h after the first dose.

2.4. Side effects

A serious class side effect of MRAs is represented by hyperkalemia. Aldosterone, by binding its receptor, stimulates the apical Na–K-ATPase pump and luminal potassium channel activity into the late distal convoluted tubules and the distal collecting ducts, thus promoting luminal potassium excretion. Therefore, antagonism of the aldosterone receptor decreases luminal K excretion, promoting accretion of potassium in the body. When severe, hyperkalemia may precipitate cardiomyocyte membrane potential destabilization and unstable ventricular arrhythmias [17]. Although serious hyperkalemia occurred in about 2–3% of MRA treated patients in randomized clinical trial, 19, 22 rates as high as 10% in the community have been reported [18]. The risk of serious hyperkalemia is minimized by routine serum potassium and renal function monitoring, and avoidance of concurrent pharmacotherapies associated with potassium retention or diet and dietary supplements containing high levels of potassium. Of particular interest, a novel therapeutic agent called RLY5016 (oral, a non-absorbed, potassium-binding polymer) prevented hyperkalemia in patients with HF receiving standard therapy and spironolactone [23].

Other important side-effects are linked to spironolactone cross-reaction with androgen-receptors. The incidence of spironolactone-associated breast tenderness and gynecomastia reported in clinical trials is 6.9% to 10% for men and typically occurs at doses 50 mg/d [19]. Generally, these side effects resolve with drug cessation. Spironolactone may also lower testosterone levels, causing erectile dysfunction in male and menstrual irregularities in female; when present, these side effects increase rates of medication noncompliance [7]. In contrast to spironolactone, eplerenone has 100–1000 lower affinity to testosterone and progesterone receptors, meaning less pronounced, placebo-equivalent, sexual side effects [22].

2.5. Future research on aldosterone antagonists and synthase inhibitors

There is an active research for novel aldosterone antagonists with similar potency as spironolactone and even higher specificity than eplerenone such as SM-368229 from Dainippon Sumitomo Pharma Co., Ltd. (Osaka, Japan) [24]. A novel approach is to move from receptor blockade to the inhibition of aldosterone synthesis [25]. At least three compounds with this mechanism of action were identified: FAD286 (Novartis, Basel, Switzerland), LCI699 (Novartis, Basel, Switzerland) and SPP2745 (Novartis, Basel, Switzerland) [26]. FAD286, an enantiomer of fadrazole with an inhibitory effect on aldosterone synthase, has been shown to reduce blood pressure, attenuate myocardial and renal injury 27, 28 and normalize redox status in rats after myocardial infarction [29]. SPP2745 suppressed aldosterone levels and also provided cardiac, renal and vascular protective effects when administered on top of conventional therapy [26]. Finally, LCI699 suppressed aldosterone levels and lowered blood pressure by 4.1 mm Hg in 14 hypertensive patients, but also latently inhibited cortisone formation [30]. Inhibition of aldosterone synthase should prevent reactive increase in aldosterone levels and adverse androgen receptor-related effects, since these new drugs do not have a steroid structure. On the other hand, mineralocorticoid receptors are also stimulated by cortisol and other ligands that are released in conditions of augmented oxidative stress [31]. Aldosterone synthase inhibitors will not oppose these aldosterone-independent mechanisms that might be blocked by spironolactone or eplerenone. Future studies will show whether what these theoretical concerns will have as clinical implications.

3.1. Heart failure with reduced ejection fraction (HF-REF)

As previously discussed, aldosterone is regarded as a potent mediator of cardiac remodeling in left ventricular dysfunction and therapy with MRA has a role in preventing these maladaptive effects in patients with CHF and left ventricular (LV) systolic dysfunction. A number of large randomized controlled trials (RCTs) investigating the benefit of aldosterone antagonists in patients with systolic heart failure have demonstrated a clear reduction in death and cardiovascular morbidity 19, 22, 32, as well as benefits in systolic and diastolic patterns (Table1).

Three landmark randomized controlled clinical trials have shown the benefits of MRA therapy with reduction of morbidity and mortality among patients with reduced LV ejection fraction (LVEF), Table2. Randomized ALdactone Evaluation Study (RALES) published in 1999 was the first large, randomized, double-blind, placebo-controlled trial on a mineralocorticoid receptor antagonist in patients with heart failure (HF) [19]. RALES evaluated the benefits of spironolactone in a total of 1663 patients with severe heart failure (functional class New York Heart Association III and IV) and decreased LVEF (EF ≤ 35%) who were being treated with standard therapy for heart failure. Patients were randomly assigned to receive spironolactone (25–50 mg daily, mean daily study dose 26 mg) or placebo for a mean follow-up period of 24 months. The primary end-point was all-cause mortality. Patients randomized to spironolactone had a significantly lower risk of death from any cause when compared with placebo (35% vs 46%, RR 0.70, P < 0.001). Spironolactone also reduced cause-specific mortality. Sudden death was reduced by 29% and death due to progressive heart failure was reduced by 36% (RR 0.64). In the spironolactone treated group hospitalization for worsening heart failure was 35% lower. In addition, patients who received spironolactone had a significant improvement in their symptoms of heart failure assessed using NYHA functional class. Safety of spironolactone was acceptable: patients randomized to spironolactone had an increase in median potassium concentration of 0.3 mEq/L, but the incidence of severe hyperkalemia (serum potassium ≥ 6 mEq/L) in the treatment group was only 2% and not significantly different from placebo group, (P = 0.42). A recent post-hoc analysis showed that African American (AA) subjects with HF enrolled in this study exhibited less hyperkalemia and more hypokalemia with spironolactone compared with non-AAs and seemed to derive less clinical benefit: in non-AA participants, spironolactone was associated with a 30% reduction in the risk for all-cause mortality (adjusted hazard ratio, 0.70) and a 36% reduction in the risk for the composite outcome of death or hospitalization for HF (adjusted hazard ratio); in the AA participants, spironolactone use was associated with no effect on mortality (adjusted hazard ratio, 0.84) or death or hospitalizations for HF (adjusted hazard ratio, 1.18). These findings suggest that safety and efficacy of mineralocorticoid receptor antagonists may differ by race but mechanisms underlying this difference are unclear at this moment so further study will be necessary [33]. Additional insights from RALES suggest that spironolactone limited the excessive extracellular matrix turnover in the heart, which may contribute to prevention of adverse cardiac remodeling in patients with HF [34].

The knowledge about aldosterone as a mediator of myocardial remodeling and fibrosis is the rationale at the basis of a second important trial on patients with LVEF and heart failure, which evaluated patients with recent acute myocardial infarction: the Eplerenone Post-myocardial infarction Heart failure Efficacy and Survival Study (EPHESUS). This trial demonstrated the benefit of aldosterone receptor antagonists in patients with LVEF < 40% after MI. Patients (n = 6642) included those post-MI who had left ventricular dysfunction and either diabetes or clinical evidence of HF and they were randomized to eplerenone 25 mg/d or placebo for 4 weeks, after which the dose of eplerenone was increased to a maximum of 50 mg/die. Patients were followed for an average of 16 months. In EPHESUS, MRA therapy significantly reduced mortality and morbidity. Eplerenone reduced the risk of death from any cause and death for cardiovascular causes by 15% and 13%, respectively. Eplerenone also reduced time to death from any cause (RR 0.85, P = 0.008) and the composite of time to cardiovascular death or first cardiovascular hospitalization (RR 0.87, P = 0.02) when compared with placebo. Serious hyperkalemia (≥ 6 mEq/L) was reported more often in the eplerenone group. However, drug discontinuation was similar between the two (4.5% vs 4.4%). An interesting result in EPHESUS was that the survival advantage with eplerenone treatment was seen as early as 30 days after initiation of therapy. In a similar study evaluating MRA therapy on post-infarction LV remodeling, in patients with first acute anterior MI after revascularization, it was found that combination of spironolactone and ACE-inhibitors prevented post-infarction LV remodeling better than ACE-inhibitors alone [35].

These findings are in line with reports that high plasma levels of aldosterone discovered during hospitalization for an acute ST-segment elevation myocardial infarction are an independent prognostic marker for future CHF, ventricular arrhythmia, and cardiac death 36, 37.

About Acute HF, the usefulness of aldosterone receptor antagonists in the setting of acute decompensated heart failure has not been determined. Current evidence from RALES and EPHESUS supporting the use of aldosterone receptor antagonists is based on long-term clinical outcome data, but the acute effects of these agents are less established. Evidence suggests that aldosterone antagonists may improve cardiac vagal control (including heart rate variability and baroreflex sensitivity) immediately after intravenous administration, an effect that may be beneficial in decompensated heart failure and MI [38].

RALES only evaluated patients with HF in class NYHA classes III to IV. Recently, evidence from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF) study suggests that also patients with mild heart failure benefit substantially from aldosterone receptor antagonist therapy [22]. This study enrolled 2737 patients with NYHA class II systolic heart failure and left ventricular ejection fraction ≤ 35% (patients with LVEF > 30% but < 35% could be included if QRS complex was > 130 ms on ECG) randomly assigned to receive eplerenone (up to 50 mg daily) or placebo. The addition of eplerenone to optimal therapy reduced the risk of cardiovascular death or hospitalization for HF (18.3% vs 25.9%, HR 0.63, P < 0.001). Benefits of eplerenone therapy were also observed in several secondary outcomes including all-cause mortality (HR 0.76, P = 0.008). Focusing on hospitalization, post-hoc analyses of the EMPHASIS-HF data suggested that patients with mild HF and treated with eplerenone had significantly fewer HF hospitalizations especially within the first year. In addition, eplerenone not only reduces the risk of first admissions but also decreases the likelihood of second and subsequent admissions for heart failure (and, therefore, the overall number of patients hospitalized and the total number of admissions for any reason) [39]. Eplerenone was generally well tolerated in EMPHASIS-HF with the most frequent adverse event being hyperkalemia, but the incidence of severe hyperkalemia (defined as serum potassium > 6 mEq/L) was not different among eplerenone and placebo-treated patients (2.5 vs. 1.9%, P = 0.29). Sexual adverse events (e.g. gynecomastia) occurred in < 1% of eplerenone recipients, reflecting the selectivity of eplerenone for mineralocorticoid receptors. A recent analysis of EMPHASIS-HF confirms that benefits of eplerenone therapy were evident even in the sub-group of patients receiving high doses of standard background therapies (ACE-i, or angiotensin receptor blocker, β-blocker, or both drug classes) [40]. Finally, another recent post-hoc analysis from EMPHASIS-HF, categorized subjects enrolled in this trial into three groups of low-, medium-, and high-risk based on strong independent risk factors identified using multivariable analysis: age, sex, systolic blood pressure, estimated glomerular filtration rate, diabetes, BMI, hemoglobin, prior HF, prior myocardial infarction, and heart rate. Rates (per 100 patient-years) of the primary outcome in patients treated with were 7.6, 19.0, and 39.4 in the low, medium and high risk group, respectively. Among patients treated with eplerenone, these rates were 5.6, 12.2, and 24.2, respectively. Therefore, eplerenone was beneficial across all risk categories. The benefit derived from treatment was greatest among those at highest risk [41].

Based on the data of these three trials, current European Society of Cardiology (ESC) Guidelines and American College of Cardiology (ACC)/American Heart Association (AHA) Guidelines are coherent in strongly recommending the use of ARA with a high level of evidence in patients with reduce LVEF and symptoms of HF (Table3) 42, 43, 44. Guidelines warn that, although in clinical trials hyperkalemia and worsening renal function were uncommon, they may occur more frequently in ordinary clinical practice, especially in the elderly. Therefore, an important limitation of the use of MRA is represented by an impaired renal function (i.e. serum creatinine is greater than 2.5 mg/dL in men or greater than 2.0 mg/dL in women or estimated glomerular filtration rate < 30 mL/min/1.73 m²), and/or potassium greater than 5.0 mEq/L.

Since MRAs have been shown to reduce fibrosis and remodeling among patients with reduced LVEF 20, 34, 45, 46, 47, there could be a rationale in treating even asymptomatic patients with low LVEF for preventing the progression of chronic HF. Some small studies suggested that MRA could be beneficial among asymptomatic patients with dilated cardiomyopathy, at least in reducing the risk of hospitalization [48]. However, to date there is insufficient evidence to recommend MRA among asymptomatic patients and further studies (i.e. large RCTs) are needed.

3.2. Heart failure with preserved ejection fraction (HFpEF)

Given the clear benefit of aldosterone antagonists in patients with reduce LVEF, an important question is whether there could be a role for MRA in patients with HF and preserved ejection fraction (HFpEF). HFpEF is defined as the clinical syndrome of HF, but with preserved systolic function and abnormalities in diastolic function. Patients with HFpEF have a slightly lower mortality than patients with reduced LVEF [49], however absolute mortality is still high in these patients (i.e. 12–13%/year) highlighting the need for a treatment to improve prognosis. No treatment has yet been shown, convincingly, to reduce morbidity and mortality in these patients and MRAs represent a promising class of drugs.

Various physiologic mechanisms have been implicated in the pathogenesis of HFpEF and diastolic dysfunction including increased passive ventricular stiffness due to enhanced extracellular collagen deposition and intrinsic alterations in myocyte cytoskeletal proteins [50], impaired active myocardial relaxation related to altered myocyte calcium handling and reduced myocardial energy reserve [1], 10,11 abnormal ventricular–vascular coupling and pulsatile load as a consequence of diminished aortic compliance [51], and impaired renal handling of salt and water because of increased neurohormonal activation. Since aldosterone is involved in many of these mechanisms, MRA may be useful in preventing many of the pathologic alterations in HFpEF.

Aldosterone antagonism has been shown to improve echocardiographic measurements of myocardial relaxation in patients with parossistic dyspnea and abnormal LV filling patterns [52]. A recent meta-analysis showed that MRA treatment brought benefits on early mitral inflow (E) and E wave deceleration time (DT), which may serve as surrogates for diastolic dysfunction [53]. This benefit in HFpEF is likely independent of the antihypertensive effects of these agents, because improvement in diastolic parameters have been demonstrated independent of blood pressure effect: in a randomized, double-blinded, placebo-controlled study of 30 hypertensive patients with HFpEF, spironolactone therapy (25 mg/day) over 6 months improved LV relaxation and filling patterns independent of changes in BP when compared with placebo [54]. The Aldosterone Receptor Blockade in Diastolic Heart Failure (Aldo-DHF) trial showed the benefits of spironolactone on diastolic function in patients with HFpEF [55]. The Aldo-DHF trial was a multicenter, randomized, double-blind, placebo-controlled trial of 422 patients with chronic NYHA class II or III symptoms, preserved LVEF of ≥ 50%, and echocardiographic evidence of diastolic dysfunction, who were randomly assigned to spironolactone 25 mg once daily (n = 213) or placebo (n = 209). Co-primary endpoints were changes in diastolic function (E/e′) on echocardiography and maximal exercise capacity (peak VO₂) on cardiopulmonary exercise testing at 12 months. MRA improved diastolic function (E/e′ decreased from 12.7 to 12.1 with spironolactone and increased from 12.8 to 13.6 with placebo) but therapy with spironolactone failed to improve maximal exercise capacity or symptoms. Therefore it is not clear whether improvements of surrogate end-point (such as diastolic function) may have clinical relevance in patients with HFpEF.

The Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial was the most recent and the largest RCT that evaluated MRA therapy in HFpEF population. The trial randomized 3445 patients with HF and LVEF > 45% to receive spironolactone or placebo. It was the first trial of MRA in HFpEF sufficiently powered to detect effects on morbidity and mortality [56]. Spironolactone failed to reduce the primary endpoint consisting in the composite of CV death, hospitalization for the management of HF, or aborted cardiac arrest (18.6% spironolactone vs. 20.4% placebo, HR = 0.89, 95% CI 0.77–1.04, P = 0.14). However, patients randomized to spironolactone were less likely to be hospitalized for HF compared to those on placebo (12.0% vs. 14.2%, HR 0.83, 95% CI 0.69–0.99, P = 0.042). There were no significant differences between the groups in deaths or hospitalizations from any cause. Hyperkalemia (18.7% vs. 9.1%, P < 0.001) and renal failure, defined as doubling of creatinine > 2 upper limit of normal, were both significantly higher in the spironolactone arm. Although the overall results of TOPCAT are negative, spironolactone is the first agent who reduced HF hospitalization rate in HFpEF population, with no increase in mortality. This is an encouraging finding since hospitalizations for HF represent a major burden in these patients, which impacts quality of life. Moreover a post-hoc analysis of patients enrolled in the Western regions suggested a potential efficacy of spironolactone in reducing primary end-point (HR 0.82 (95% CI 0.69–0.98)) [57]. This finding and the reduction in HF hospitalizations with spironolactone are hypothesis generating and deserve further study.

3.3. Effects on fibrosis, remodeling and arterial stiffening

The efficacy of MRA in reducing fibrosis has been first demonstrated in animal models. A study by Lacolley et al. on old normotensive rats showed that cardiac collagen density and carotid collagen and elastin densities and contents were significantly decreased in association with an increase of carotid distensibility in subjects after eight-week treatment with spironolactone compared with controls [58]. The same results were observed in a study conducted on rats in which spironolactone was demonstrated able to prevent the perivascular/interstitial fibrosis and scarring [59]. These observations in animal models encouraged to study MRA in humans [60]. The association between aldosterone and left ventricular remodeling has been shown previously in a community-based sample. In 2119 participants in the Framingham Offspring Study, the aldosterone–renin ratio was positively associated with both concentric and eccentric left ventricular hypertrophy [61]. A follow-up study performed in the same community-based sample related elevated levels of pro-collagen type III aminoterminal peptide (PIIINP), a marker of matrix synthesis, or tissue inhibitor of matrix metalloproteinase-1 (TIMP1) for mortality risk [15]. Several studies suggest that MRAs are effective in reducing myocardial fibrosis. Preclinical studies have shown that these changes in extracellular matrix turnover are not solely the result of fibroblast aldosterone and MR activation, and that cardiomyocytes themselves do participate in extracellular matrix remodeling [62]. Serum levels of collagen markers have been proposed as noninvasive indicators of myocardial collagen content, and they are well correlated [63]. A subgroup analysis from the RALES trial revealed a highly significant decrease in the serum levels of PIIINP among patients treated with spironolactone [34]. Moreover, a sub-study of EPHESUS involving 476 patients showed that by 6 months and persisting at 9 months, procollagen type I and III amino-terminal peptide (PINP and PIIINP) levels were significantly lower among patients randomized to eplerenone, suggesting a positive anti-fibrotic and anti-remodeling action of eplerenone [64]. MRA therapy has been shown to prevent a progressive increase in markers of collagen turnover and improved diastolic function also in patients with HFpEF 65, 66. Other studies documented a substantial regression of myocardial fibrosis and a significant amelioration of LV diastolic dysfunction in patients with an elevated serum marker of myocardial collagen accumulation [67]. A recent meta-analysis further confirmed that administration of MRA is correlated with a reduction in serum PIIINP for patients with HF or myocardial infarction [53]. Finally, recent randomized controlled trial on 113 obese patients impaired early diastolic mitral annular velocity, randomized to spironolactone 25 mg/day or placebo for 6 months, and showed significant improvements in myocardial deformation, peak early diastolic velocity (Em) and E/e′ with a simultaneous decrease in PICP and PIIINP in spironolactone group [68].

Previous epidemiological studies have demonstrated that increased pulse wave velocity (PWV), a marker of arterial stiffness, is associated with an increased risk of cardiovascular morbidity and mortality 69, 70. Arterial stiffening is frequent in HF patients and has a negative impact on functional capacity and worsening of HF 71, 72, 73. Elastic artery stiffening is due to degenerated elastic fibers, increased collagenous material, hypertrophied vascular smooth muscle layer, increased pro-inflammatory cytokines and increased calcium deposition resulting in a less compliant media layer [74]. Previous studies have revealed that aldosterone increases the collagen content and fibronectin accumulation in the arterial wall 75, 76. A study by Park et al. demonstrated that serum aldosterone is significantly associated with central aortic PWV in 438 hypertensive patients, suggesting a possible role for aldosterone in developing central aortic stiffness and increased PWV in hypertensive patients [77]. Studies on animal models showed a positive action of MRA on arterial and myocardial wall stiffness by reducing fibrosis 58, 75, 76, 78. Similar results have been showed in human subjects: PWV decreased significantly after six months spironolactone treatment in hypertensive elderly subjects [79]. Both spironolactone and eplerenone have been shown to decrease LV mass with a reduction in the prevalence of hypertrophy in treated patients from 30% to 7% [80]. These data suggest that MRA could be effective in reducing myocardial remodeling in hypertensive subjects and may slow down the progression from hypertensive heart disease to congestive heart failure.

3.4. Arrhythmias

Arrhythmias are frequent among patients with HF and sudden cardiac death (SCD) due to ventricular arrhythmias represents a major cause of death in CHF. Aldosterone has been suggested to have pro-arrhythmic effects and MRAs have been shown to have anti-arrhythmic action. Particularly, among patients with HF, MRA demonstrated to reduce the incidence of ventricular arrhythmias and SCD [81]. In both the RALES and EPHESUS trials aldosterone blockade was associated to a reduction of sudden death events. In the RALES trial, spironolactone reduced the incidence of sudden death by 29% (RR 0.71, P = 0.02) [19]. In EPHESUS, eplerenone significantly reduced sudden death by 21% (RR 0.79, P = 0.03) [32]. Eplerenone was also associated with significant reductions in sudden death and total mortality in the early post-MI period (first 30 days), when patients are at the greatest risk of SCD [82]. In a recent meta-analysis the therapy with MRA was associated with a 23% risk reduction of sudden cardiac death among patients with LV systolic dysfunction, with similar benefits for spironolactone and eplerenone [83]. Although the exact mechanism that underlies the anti-arrhythmic properties of MRA is not known, many hypotheses have been proposed. Probably MRAs suppress the arrhythmogenic effects of aldosterone at multiple levels. First, MRAs contribute to modulation of renin–angiotensin–aldosterone system reducing ventricular remodeling in HF and in post-MI patients. At the tissue level, they limit potassium and magnesium loss and reduce myocardial fibrosis and hypertrophy 84, 85, 86. At the cellular level, MRAs suppress the combined effect of aldosterone on select calcium and potassium currents, which prolongs the ventricular action potential duration and lowers the threshold for ventricular arrhythmias [81]. With whole-cell patch-clamp methods, exposure to aldosterone for 48 h was shown to increase delayed after-depolarizations in experimental models with cardiac overexpression of human MR. This finding was attributed to MR-mediated ion channel remodeling, especially the down-regulation of FK506-binding proteins, which regulate the ryanodine receptor macromolecular complex. The resulting increased activity of ryanodine receptor leads to long-lasting and broader calcium sparks and, consequently, to prolonged ventricular repolarization [14]. Thus, one effect of MR antagonism would be to decrease prolonged cardiomyocyte calcium sparks and potentially limit arrhythmias through this mechanism. Moreover, MRAs reduce the release of norepinephrine from sympathetic nerve terminals enhancing parasympathetic activity and promoting its direct reuptake into the myocyte reducing ventricular arrhythmias 87, 88.

In addition to its potential role in the prevention of ventricular arrhythmias, aldosterone receptor antagonism has also a role in the prevention of atrial arrhythmias. Atrial fibrillation is the most common sustained arrhythmia in congestive heart failure. In rat models spironolactone reduces the adverse structural changes that occur in congestive heart failure, including atrial fibrosis and atrial remodeling [89]. Eplerenone has been shown to suppress the inducibility of atrial tachyarrhythmias in dog models [90]. Meta-analysis of several studies demonstrates that ARBs and ACE-inhibitors are associated with less atrial fibrillation [91]. It is possible that additional blockade of the RAAS system may also be particularly useful to prevent recurrence of atrial fibrillation after cardioversion as well [92]. In EMPHASIS-HF trial, the incidence of new onset atrial fibrillation or flutter was a secondary endpoint. A sub-analysis, which included 1794 patients without history of atrial fibrillation or flutter, showed that eplerenone reduced the incidence of new atrial fibrillation: 25 of 911 eplerenone-treated patients (2.7%) versus 40 of 883 patients (4.5%) in the placebo group (hazard ratio [HR]: 0.58, P < 0.034). Background use of ACE inhibitor or ARBs did not influence the results [93]. It has been proposed that aldosterone receptor blockade may serve as a primary prevention agent of sudden cardiac death in patient populations at risk, including long QT syndrome, Brugada syndrome, and hypertrophic cardiomyopathy [94]. Despite that potential antiarrhythmic mechanisms of MRA exist and the retrospective data from previous studies are encouraging, further prospective studies are necessary to prove the efficacy of these drugs in preventing arrhythmias.

Available online 19 March 2014

1. Weber K.T. Aldosterone in congestive heart failure. N Engl J Med. 2001;345:1689–1697. [PubMed] [Google Scholar]

2. Brown N.J. Eplerenone: cardiovascular protection. Circulation. 2003;107:2512–2518. [PubMed] [Google Scholar]

3. Struthers A.D. The clinical implications of aldosterone escape in congestive heart failure. Eur J Heart Fail. 2004;6:539–545. [PubMed] [Google Scholar]

4. Mohammed S.F., Ohtani T., Korinek J., Lam C.S., Larsen K., Simari R.D. Mineralocorticoid accelerates transition to heart failure with preserved ejection fraction via “nongenomic effects” Circulation. 2010;122:370–378. [PMC free article] [PubMed] [Google Scholar]

5. Brilla C.G., Zhou G., Matsubara L., Weber K.T. Collagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin II and aldosterone. J Mol Cell Cardiol. 1994;26:809–820. [PubMed] [Google Scholar]

6. Fraccarollo D., Galuppo P., Bauersachs J. Mineralocorticoid receptor antagonism and cardiac remodeling in ischemic heart failure. Curr Med Chem Cardiovasc Hematol Agents. 2004;2:287–294. [PubMed] [Google Scholar]

7. Brilla C.G. Aldosterone and myocardial fibrosis in heart failure. Herz. 2000;25:299–306. [PubMed] [Google Scholar]

8. Lijnen P., Petrov V. Induction of cardiac fibrosis by aldosterone. J Mol Cell Cardiol. 2000;32:865–879. [PubMed] [Google Scholar]

9. Nakamura T., Kataoka K., f*ckuda M., Nako H., Tokutomi Y., Dong Y.F. Critical role of apoptosis signal-regulating kinase 1 in aldosterone/salt-induced cardiac inflammation and fibrosis. Hypertension. 2009;54:544–551. [PubMed] [Google Scholar]

10. Perico N., Benigni A., Remuzzi G. Present and future drug treatments for chronic kidney diseases: evolving targets in renoprotection. Nat Rev Drug Discov. 2008;7:936–953. [PubMed] [Google Scholar]

11. Assomull R.G., Prasad S.K., Lyne J., Smith G., Burman E.D., Khan M. Cardiovascular magnetic resonance, fibrosis, and prognosis in dilated cardiomyopathy. J Am Coll Cardiol. 2006;48:1977–1985. [PubMed] [Google Scholar]

12. Iles L., Pfluger H., Lefkovits L., Butler M.J., Kistler P.M., Kaye D.M. Myocardial fibrosis predicts appropriate device therapy in patients with implantable cardioverter-defibrillators for primary prevention of sudden cardiac death. J Am Coll Cardiol. 2011;57:821–828. [PubMed] [Google Scholar]

13. Swynghedauw B. Molecular mechanisms of myocardial remodeling. Physiol Rev. 1999;79:215–262. [PubMed] [Google Scholar]

14. Gómez A.M., Rueda A., Sainte-Marie Y., Pereira L., Zissimopoulos S., Zhu X. Mineralocorticoid modulation of cardiac ryanodine receptor activity is associated with downregulation of FK506-binding proteins. Circulation. 2009;119:2179–2187. [PubMed] [Google Scholar]

15. Velagaleti R.S., Gona P., Sundström J., Larson M.G., Siwik D., Colucci W.S. Relations of biomarkers of extracellular matrix remodeling to incident cardiovascular events and mortality. Arterioscler Thromb Vasc Biol. 2010;30:2283–2288. [PMC free article] [PubMed] [Google Scholar]

16. Tang W.H., Parameswaran A.C., Maroo A.P., Francis G.S. Aldosterone receptor antagonists in the medical management of chronic heart failure. Mayo Clin Proc. 2005;80:1623–1630. [PubMed] [Google Scholar]

17. Cittadini A., Monti M.G., Isgaard J., Casaburi C., Strömer H., Di Gianni A. Aldosterone receptor blockade improves left ventricular remodeling and increases ventricular fibrillation threshold in experimental heart failure. Cardiovasc Res. 2003;58:555–564. [PubMed] [Google Scholar]

18. Schafer A., Fraccarollo D., Hildemann S.K., Tas P., Ertl G., Bauersachs J. Addition of the selective aldosterone receptor antagonist eplerenone to ACE inhibition in heart failure: effect on endothelial dysfunction. Cardiovasc Res. 2003;58:655–662. [PubMed] [Google Scholar]

19. Pitt B., Zannad F., Remme W.J., Cody R., Castaigne A., Perez A. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709–717. [PubMed] [Google Scholar]

20. Boccanelli A., Mureddu G.F., Cacciatore G., Clemenza F., Di Lenarda A., Gavazzi A. Anti-remodelling effect of canrenone in patients with mild chronic heart failure (AREA IN-CHF study): final results. Eur J Heart Fail. 2009;11:68–76. [PubMed] [Google Scholar]

21. Modena M.G., Aveta P., Menozzi A., Rossi R. Aldosterone inhibition limits collagen synthesis and progressive left ventricular enlargement after anterior myocardial infarction. Am Heart J. 2001;141:41–46. [PubMed] [Google Scholar]

22. Zannad F., McMurray J.J., Krum H., van Veldhuisen D.J., Swedberg K., Shi H. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364:11–21. [PubMed] [Google Scholar]

23. Pitt B., Anker S.D., Bushinsky D.A., Kitzman D.W., Zannad F., Huang I.Z., PEARL-HF Investigators Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial. Eur Heart J. 2011;32:820–828. [PMC free article] [PubMed] [Google Scholar]

24. Nariai T., Fujita K., Mori M., Katayama S., Hori S., Matsui K. SM-368229, a novel selective and potent non-steroidal mineralocorticoid receptor antagonist with strong urinary Na⁺ excretion activity. J Pharmacol Sci. 2011;115:346–353. [PubMed] [Google Scholar]

25. Steckelings U.M., Paulis L., Unger T., Bader M. Emerging drugs which target the renin–angiotensin–aldosterone system. Expert Opin Emerg Drugs. 2011;16:619–630. [PubMed] [Google Scholar]

26. Paulis L., Unger T. Novel therapeutic targets for hypertension. Nat Rev Cardiol. 2010;7:431–441. [PubMed] [Google Scholar]

27. Fiebeler A., Nussberger J., Shagdarsuren E., Rong S., Hilfenhaus G., Al-Saadi N. Aldosterone synthase inhibitor ameliorates angiotensin II-induced organ damage. Circulation. 2005;111:3087–3094. [PubMed] [Google Scholar]

28. Lea W.B., Kwak E.S., Luther J.M., Fowler S.M., Wang Z., Ma J. Aldosterone antagonism or synthase inhibition reduces end-organ damage induced by treatment with angiotensin and high salt. Kidney Int. 2009;75:936–944. [PMC free article] [PubMed] [Google Scholar]

29. Mulder P., Mellin V., Favre J., Vercauteren M., Remy-Jouet I., Monteil C. Aldosterone synthase inhibition improves cardiovascular function and structure in rats with heart failure: a comparison with spironolactone. Eur Heart J. 2008;29:2171–2179. [PubMed] [Google Scholar]

30. Amar L., Azizi M., Menard J., Peyrard S., Watson C., Plouin P.F. Aldosterone synthase inhibition with LCI699: a proof-of-concept study in patients with primary aldosteronism. Hypertension. 2010;56:831–838. [PubMed] [Google Scholar]

31. Funder J.W. Mineralocorticoid receptors: distribution and activation. Heart Fail Rev. 2005;10:15–22. [PubMed] [Google Scholar]

32. Pitt B., Remme W., Zannad F., Neaton J., Martinez F., Roniker B. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309–1321. [PubMed] [Google Scholar]

33. Vardeny O., Cavallari L.H., Claggett B., Desai A.S., Anand I., Rossignol P. Race influences the safety and efficacy of spironolactone in severe heart failure. Circ Heart Fail. 2013;6:970–976. [PubMed] [Google Scholar]

34. Zannad F., Alla F., Dousset B., Perez A., Pitt B. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators. Circulation. 2000;102:2700–2706. [PubMed] [Google Scholar]

35. Hayashi M., Tsutamoto T., Wada A., Tsutsui T., Ishii C., Ohno K. Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction. Circulation. 2003;107:2559–2565. [PubMed] [Google Scholar]

36. Palmer B.R., Pilbrow A.P., Frampton C.M., Yandle T.G., Skelton L., Nicholls M.G. Plasma aldosterone levels during hospitalization are predictive of survival post-myocardial infarction. Eur Heart J. 2008;29:2489–2496. [PubMed] [Google Scholar]

37. Delyani J.A., Robinson E.L., Rudolph A.E. Effect of a selective aldosterone receptor antagonist in myocardial infarction. Am J Physiol Heart Circ Physiol. 2001;281:H647–H654. [PubMed] [Google Scholar]

38. Fletcher J., Buch A.N., Routledge H.C., Chowdhary S., Coote J.H., Townend J.N. Acute aldosterone antagonism improves cardiac vagal control in humans. J Am Coll Cardiol. 2004;43:1270–1275. [PubMed] [Google Scholar]

39. Rogers J.K., McMurray J.J., Poco*ck S.J., Zannad F., Krum H., van Veldhuisen D.J. Eplerenone in patients with systolic heart failure and mild symptoms: analysis of repeat hospitalizations. Circulation. 2012;126:2317–2323. [PubMed] [Google Scholar]

40. Krum H., Shi H., Pitt B., McMurray J., Swedberg K., van Veldhuisen D.J. Clinical benefit of eplerenone in patients with mild symptoms of systolic heart failure already receiving optimal best practice background drug therapy: analysis of the EMPHASIS-HF study. Circ Heart Fail. 2013;6:711–718. [PubMed] [Google Scholar]

41. Collier T.J., Poco*ck S.J., McMurray J.J., Zannad F., Krum H., van Veldhuisen D.J. The impact of eplerenone at different levels of risk in patients with systolic heart failure and mild symptoms: insight from a novel risk score for prognosis derived from the EMPHASIS-HF trial. Eur Heart J. 2013;34:2823–2829. [PubMed] [Google Scholar]

42. Writing Committee Members, Yancy C.W., Jessup M., Bozkurt B., Butler J., Casey D.E., Jr., Drazner M.H. ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;128:e240–e319. [PubMed] [Google Scholar]

43. McMurray J.J., Adamopoulos S., Anker S.D., Auricchio A., Böhm M., Dickstein K. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012;33:1787–1847. [PubMed] [Google Scholar]

44. Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC), Steg P.G., James S.K., Atar D., Badano L.P., Blömstrom-Lundqvist C., Borger M.A. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012;33:2569–2619. [PubMed] [Google Scholar]

45. Vizzardi E., D'Aloia A., Giubbini R., Bordonali T., Bugatti S., Pezzali N. Effect of spironolactone on left ventricular ejection fraction and volumes in patients with class I or II heart failure. Am J Cardiol. 2010;106:1292–1296. [PubMed] [Google Scholar]

46. Udelson J.E., Feldman A.M., Greenberg B., Pitt B., Mukherjee R., Solomon H.A. Randomized, double-blind, multicenter, placebo-controlled study evaluating the effect of aldosterone antagonism with eplerenone on ventricular remodeling in patients with mild-to-moderate heart failure and left ventricular systolic dysfunction. Circ Heart Fail. 2010;3:347–353. [PubMed] [Google Scholar]

47. Chan A.K., Sanderson J.E., Wang T., Lam W., Yip G., Wang M. Aldosterone receptor antagonism induces reverse remodeling when added to angiotensin receptor blockade in chronic heart failure. J Am Coll Cardiol. 2007;50:591–596. [PubMed] [Google Scholar]

48. Vizzardi E., Nodari S., Caretta G. Effects of spironolactone on long-term mortality and morbidity in patients with heart failure and mild or no symptoms. Am J Med Sci. 2014;347(4):271–276. [PubMed] [Google Scholar]

49. Meta-analysis Global Group in Chronic Heart F The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis. Eur Heart J. 2012;33:1750–1757. [PubMed] [Google Scholar]

50. Borlaug B.A., Paulus W.J. Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. Eur Heart J. 2011;32:670–679. [PMC free article] [PubMed] [Google Scholar]

51. Desai A.S., Mitchell G.F., Fang J.C., Creager M.A. Central aortic stiffness is increased in patients with heart failure and preserved ejection fraction. J Card Fail. 2009;15:658–664. [PubMed] [Google Scholar]

52. Mottram P.M., Haluska B., Leano R., Cowley D., Stowasser M., Marwick T.H. Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure. Circulation. 2004;110:558–565. [PubMed] [Google Scholar]

53. Li X., Qi Y., Li Y. Impact of mineralocorticoid receptor antagonists on changes in cardiac structure and function of left ventricular dysfunction: a meta-analysis of randomized controlled trials. Circ Heart Fail. 2013;6:156–165. [PubMed] [Google Scholar]

54. Grandi A.M., Imperiale D., Santillo R. Aldosterone antagonist improves diastolic function in essential hypertension. Hypertension. 2002;40:647–652. [PubMed] [Google Scholar]

55. Edelmann F., Wachter R., Schmidt A.G. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. JAMA. 2013;309:781–791. [PubMed] [Google Scholar]

56. Shah S.J., Heitner J.F., Sweitzer N.K. Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial. Circ Heart Fail. 2013;6:184–192. [PMC free article] [PubMed] [Google Scholar]

57. Medscape; 18 Nov 2013. Aldo-antagonist falls short but impresses in preserved-EF heart failure: TOPCAT. [Google Scholar]

58. Lacolley P., Safar M.E., Lucet B., Ledudal K., Labat C., Benetos A. Prevention of aortic and cardiac fibrosis by spironolactone in old normotensive rats. J Am Coll Cardiol. 2001;37:662–667. [PubMed] [Google Scholar]

59. Brilla C.G., Weber K.T. Reactive and reparative myocardial fibrosis in arterial hypertension in the rat. Cardiovasc Res. 1992;26:671–677. [PubMed] [Google Scholar]

60. Pfeffer M.A., Braunwald E. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation. 1990;81:1161–1172. [PubMed] [Google Scholar]

61. Velagaleti R.S., Gona P., Levy D., Velagaleti R.S., Gona P., Levy D. Relations of biomarkers representing distinct biological pathways to left ventricular geometry. Circulation. 2008;118:2252–2258. [5p following 8] [PMC free article] [PubMed] [Google Scholar]

62. Leopold J.A. Aldosterone, mineralocorticoid receptor activation, and cardiovascular remodeling. Circulation. 2011;124:e466–e468. [PMC free article] [PubMed] [Google Scholar]

63. Lopez B., Gonzalez A., Varo N., Laviades C., Querejeta R., Diez J. Biochemical assessment of myocardial fibrosis in hypertensive heart disease. Hypertension. 2001;38:1222–1226. [PubMed] [Google Scholar]

64. Iraqi W., Rossignol P., Angioi M. Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study. Circulation. 2009;119:2471–2479. [PubMed] [Google Scholar]

65. Mak G.J., Ledwidge M.T., Watson C.J. Natural history of markers of collagen turnover in patients with early diastolic dysfunction and impact of eplerenone. J Am Coll Cardiol. 2009;54:1674–1682. [PubMed] [Google Scholar]

66. Edwards N.C., Ferro C.J., Kirkwood H. Effect of spironolactone on left ventricular systolic and diastolic function in patients with early stage chronic kidney disease. Am J Cardiol. 2010;106:1505–1511. [PubMed] [Google Scholar]

67. Izawa H., Murohara T., Nagata K. Mineralocorticoid receptor antagonism ameliorates left ventricular diastolic dysfunction and myocardial fibrosis in mildly symptomatic patients with idiopathic dilated cardiomyopathy: a pilot study. Circulation. 2005;112:2940–2945. [PubMed] [Google Scholar]

68. Kosmala W., Przewlocka-Kosmala M., Szczepanik-Osadnik H., Mysiak A., Marwick T.H. Fibrosis and cardiac function in obesity: a randomised controlled trial of aldosterone blockade. Heart. 2013;99:320–326. [PubMed] [Google Scholar]

69. Laurent S., Boutouyrie P., Asmar R. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension. 2001;37:1236–1241. [PubMed] [Google Scholar]

70. Laurent S., Katsahian S., Fassot C. Aortic stiffness is an independent predictor of fatal stroke in essential hypertension. Stroke. 2003;34:1203–1206. [PubMed] [Google Scholar]

71. Ooi H., Chung W., Biolo A. Arterial stiffness and vascular load in heart failure. Congest Heart Fail. 2008;14:31–36. [PubMed] [Google Scholar]

72. Patrianakos A.P., Parthenakis F.I., Karakitsos D., Nyktari E., Vardas P.E. Proximal aortic stiffness is related to left ventricular function and exercise capacity in patients with dilated cardiomyopathy. Eur J Echocardiogr. 2009;10:425–432. [PubMed] [Google Scholar]

73. Bonapace S., Rossi A., Cicoira M. Aortic distensibility independently affects exercise tolerance in patients with dilated cardiomyopathy. Circulation. 2003;107:1603–1608. [PubMed] [Google Scholar]

74. Zieman S.J., Melenovsky V., Kass D.A. Mechanisms, pathophysiology, and therapy of arterial stiffness. Arterioscler Thromb Vasc Biol. 2005;25:932–943. [PubMed] [Google Scholar]

75. Lacolley P., Labat C., Pujol A., Delcayre C., Benetos A., Safar M. Increased carotid wall elastic modulus and fibronectin in aldosterone-salt-treated rats: effects of eplerenone. Circulation. 2002;106:2848–2853. [PubMed] [Google Scholar]

76. Nehme J.A., Lacolley P., Labat C. Spironolactone improves carotid artery fibrosis and distensibility in rat post-ischaemic heart failure. J Mol Cell Cardiol. 2005;39:511–519. [PubMed] [Google Scholar]

77. Park S., Kim J.B., Shim C.Y. The influence of serum aldosterone and the aldosterone–renin ratio on pulse wave velocity in hypertensive patients. J Hypertens. 2007;25:1279–1283. [PubMed] [Google Scholar]

78. Baldo M.P., Forechi L., Morra E.A. Long-term use of low-dose spironolactone in spontaneously hypertensive rats: effects on left ventricular hypertrophy and stiffness. Pharmacol Rep. 2011;63:975–982. [PubMed] [Google Scholar]

79. Kithas P.A., Supiano M.A. Spironolactone and hydrochlorothiazide decrease vascular stiffness and blood pressure in geriatric hypertension. J Am Geriatr Soc. 2010;58:1327–1332. [PMC free article] [PubMed] [Google Scholar]

80. Pitt B., Reichek N., Willenbrock R. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation. 2003;108:1831–1838. [PubMed] [Google Scholar]

81. Ouvrard-Pascaud A., Sainte-Marie Y., Benitah J.P. Conditional mineralocorticoid receptor expression in the heart leads to life-threatening arrhythmias. Circulation. 2005;111:3025–3033. [PMC free article] [PubMed] [Google Scholar]

82. Pitt B., White H., Nicolau J. Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J Am Coll Cardiol. 2005;46:425–431. [PubMed] [Google Scholar]

83. Bapoje S.R., Bahia A., Hokanson J.E. Effects of mineralocorticoid receptor antagonists on the risk of sudden cardiac death in patients with left ventricular systolic dysfunction: a meta-analysis of randomized controlled trials. Circ Heart Fail. 2013;6:166–173. [PMC free article] [PubMed] [Google Scholar]

84. Perrier E., Kerfant B.G., Lalevee N. Mineralocorticoid receptor antagonism prevents the electrical remodeling that precedes cellular hypertrophy after myocardial infarction. Circulation. 2004;110:776–783. [PubMed] [Google Scholar]

85. Hanna S., Mac I.I. The influence of aldosterone on magnesium metabolism. Lancet. 1960;2:348–350. [PubMed] [Google Scholar]

86. Gao X., Peng L., Adhikari C.M., Lin J., Zuo Z. Spironolactone reduced arrhythmia and maintained magnesium homeostasis in patients with congestive heart failure. J Card Fail. 2007;13:170–177. [PubMed] [Google Scholar]

87. Antaloczy Z., Sebeszta M., Preda I. The effect of potassium canrenoate (aldactone) on the norepinephrine metabolism and potassium ionic currents of the heart. Adv Myocardiol. 1982;3:215–222. [PubMed] [Google Scholar]

88. Kasama S., Toyama T., Kumakura H. Effect of spironolactone on cardiac sympathetic nerve activity and left ventricular remodeling in patients with dilated cardiomyopathy. J Am Coll Cardiol. 2003;41:574–581. [PubMed] [Google Scholar]

89. Milliez P., Deangelis N., Rucker-Martin C. Spironolactone reduces fibrosis of dilated atria during heart failure in rats with myocardial infarction. Eur Heart J. 2005;26:2193–2199. [PubMed] [Google Scholar]

90. Shroff S.C., Ryu K., Martovitz N.L., Hoit B.D., Stambler B.S. Selective aldosterone blockade suppresses atrial tachyarrhythmias in heart failure. J Cardiovasc Electrophysiol. 2006;17:534–541. [PubMed] [Google Scholar]

91. Healey J.S., Baranchuk A., Crystal E. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol. 2005;45:1832–1839. [PubMed] [Google Scholar]

92. Schneider M.P., Hua T.A., Bohm M., Wachtell K., Kjeldsen S.E., Schmieder R.E. Prevention of atrial fibrillation by renin–angiotensin system inhibition a meta-analysis. J Am Coll Cardiol. 2010;55:2299–2307. [PubMed] [Google Scholar]

93. Swedberg K., Zannad F., McMurray J.J. Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure) study. J Am Coll Cardiol. 2012;59:1598–1603. [PubMed] [Google Scholar]

94. Pitt B., Pitt G.S. Added benefit of mineralocorticoid receptor blockade in the primary prevention of sudden cardiac death. Circulation. 2007;115:2976–2982. [discussion 82] [PubMed] [Google Scholar]

95. Barr C.S., Lang C.C., Hanson J., Arnott M., Kennedy N., Struthers A.D. Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol. 1995;76:1259–1265. [PubMed] [Google Scholar]

96. Tsutamoto T., Wada A., Maeda K. Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. J Am Coll Cardiol. 2001;37:1228–1233. [PubMed] [Google Scholar]

97. Cicoira M., Zanolla L., Rossi A. Long-term, dose-dependent effects of spironolactone on left ventricular function and exercise tolerance in patients with chronic heart failure. J Am Coll Cardiol. 2002;40:304–310. [PubMed] [Google Scholar]

98. Akbulut M., Ozbay Y., Ilkay E., Karaca I., Arslan N. Effects of spironolactone and metoprolol on QT dispersion in heart failure. Jpn Heart J. 2003;44:681–692. [PubMed] [Google Scholar]

99. Ozkara A., Turgut F., Selco*ki Y. Probrain natriuretic peptide for assessment of efficacy in heart failure treatment. Adv Ther. 2007;24:1233–1239. [PubMed] [Google Scholar]

100. Kasama S., Toyama T., Sumino H. Additive effects of spironolactone and candesartan on cardiac sympathetic nerve activity and left ventricular remodeling in patients with congestive heart failure. J Nucl Med. 2007;48:1993–2000. [PubMed] [Google Scholar]

101. Taheri S., Mortazavi M., Shahidi S. Spironolactone in chronic hemodialysis patients improves cardiac function. Saudi J Kidney Dis Transpl. 2009;20:392–397. [PubMed] [Google Scholar]

102. Kimura M., Ogawa H., Wakeyama T. Effects of mineralocorticoid receptor antagonist spironolactone on atrial conduction and remodeling in patients with heart failure. J Cardiol. 2011;57:208–214. [PubMed] [Google Scholar]